RSV Monoclonal Antibody for Infants Produces Significant ROI

Over the past Respiratory syncytial virus (RSV) seasons, infants have been offered a new monoclonal antibody to protect them from lower respiratory tract infections (LRTIs).

A cost-effectiveness analysis, published on May 3, 2025, estimates the economic benefits.

From the NHS perspective, over the first RSV season, Beyfortus™ (nirsevimab) in an all-infants population could be a cost-effective approach to preventing LRTIs.

These researchers concluded that a prophylaxis strategy against RSV infection targeting all infants with Beyfortus could represent a cost-effective option and support the implementation and equity of RSV prevention for all infants.

For the 2025-2026 RSV season in the United States, Beyfortus is FDA-approved and readily available.